ReviewJournal of gastroenterology2015
Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
Review in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Clinicopathological and Prognostic Implications of Epithelial-to-Mesenchymal Transition-Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study.Cancer reports (Hoboken, N.J.) · 2026Article
- The SOX gene superfamily in oncogenesis: unraveling links to ncRNAs, key pathways, chemoresistance, and gene editing approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A robust statistical approach for finding informative spatially associated pathways.Briefings in bioinformatics · 2024Article
- MiR-200b categorizes patients into pancreas cystic lesion subgroups with different malignant potential.Scientific reports · 2023Article
- Annexin A1 affects tumor metastasis through epithelial-mesenchymal transition: a narrative review.Translational cancer research · 2022Review
- Article
- The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.Signal transduction and targeted therapy · 2021Review
- Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer.Frontiers in cell and developmental biology · 2021Review
- miR-550a-3/NFIC plays a driving role in esophageal squamous cell cancer cells proliferation and metastasis partly through EMT process.Molecular and cellular biochemistry · 2020Article
- Article
- miR-934 as a Prognostic Marker Facilitates Cell Proliferation and Migration of Pancreatic Tumor by Targeting PROX1.OncoTargets and therapy · 2020Article
- Review
- Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.Molecular oncology · 2019Review
- Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1.EBioMedicine · 2019Article
- Collagen Type VI Alpha 3 Chain Promotes Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Transforming Growth Factor β (TGF-β)/Smad Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Identification of Sox6 as a regulator of pancreatic cancer development.Journal of cellular and molecular medicine · 2018Article
- Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma.Oncotarget · 2017Review
- Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer.Oncotarget · 2017Article
- Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Oncotarget · 2017Article
- miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.Molecular cancer research : MCR · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an intractable disease as a result of its rapid dissemination and resistance to conventional chemotherapy and radiotherapy. Surgical resection is the only curative therapy, but most of the tumors are unresectable at the time of diagnosis. The molecular mechanisms underlying the biological aggressiveness of this tumor type remain to be clarified. Epithelial to mesenchymal transition (EMT) is a developmental process that leads the phenotype shift from an epithelial morphology to a motile, fibroblast-like morphology. Recent studies showed that EMT is involved in the invasion and metastasis of many types of carcinomas including PDAC. In addition, PDAC cells with the EMT phenotype also exhibit chemoresistance and the cancer stem cell property. Various factors such as cytokines, growth factors, or transcriptional factors were found to promote the EMT program in PDAC cells. In this review, we summarize the current knowledge about the EMT in PDAC cells, focusing on the involvement of this process and its regulatory molecules including microRNA during the development of PDAC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.